This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Avasarala, J. R Articles by Abbey, E. E Search for Related Content PubMed PubMed Citation Articles by Avasarala, J. R Articles by Abbey, E. E Social Bookmarking                         What's this?

Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

Department of Neurology, avasaralaj{at}neuro.wustl.edu

Anne H Cross

Department of Neurology

David B Clifford

Department of Neurology

Barry A Singer

Department of Neurology

Barry A Siegel

Mallinckrodt Institute of Radiology

Elliot E Abbey

Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA

Mitoxantrone is a recently appro ved drug for patients with secondary progressive multiple sclerosis (SPMS). However, cardiac side effects limit Mitoxantrone use in SPMS and its lifetime cumulative dose should not exceed 140 mg/m². A dditionally, Mitoxantrone is contraindicated for use in SPMS patients with a baseline left ventricular ejectio n fraction (LVEF) of-50%. The goal of this study was to monitor LVEF more frequently than ordinarily recommended since experience with Mitoxantrone use in SPMS patients is limited. A n unexpected decline in LVEF in one of the SPMS patients being treated with Mitoxantrone prompted further investigation into this finding. In our clinic, 47 patients on Mitoxantrone were followed prospectively; 28 of 47 patients had received a minimum of three doses and underwent a repeat LVEF evaluation prior to their fourth dose of Mitoxantrone. O f these 28 patients, five of 28 (17.8%) had a significant decline in LVEF from baseline. It is suggested that more stringent cardiac monitoring guidelines than current Food and Drug A dministration (FDA) recommendations be used to avert potential cardiac complications in SPMS patients on Mitoxantrone.

Key Words: cardiotoxicity • left ventricular function • Mitoxantrone • monitoring • radionuclide ventriculography • secondary progressive multiple sclerosis

Multiple Sclerosis, Vol. 9, No. 1, 59-62 (2003)
DOI: 10.1191/1352458503ms896oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				F Paul, J Dorr, J Wurfel, H-P Vogel, and F Zipp Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis BMJ Case Reports, July 7, 2009; 2009(jul07_1): bcr0620092004 - bcr0620092004. [Abstract] [Full Text]

				W.-H. Piao, R. Wong, X.-F. Bai, J. Huang, D. I. Campagnolo, R. T. Dorr, T. L. Vollmer, and F.-D. Shi Therapeutic Effect of Anthracene-Based Anticancer Agent Ethonafide in an Animal Model of Multiple Sclerosis J. Immunol., December 1, 2007; 179(11): 7415 - 7423. [Abstract] [Full Text] [PDF]

				F Paul, J Dorr, J Wurfel, H-P Vogel, and F Zipp Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis J. Neurol. Neurosurg. Psychiatry, February 1, 2007; 78(2): 198 - 200. [Full Text] [PDF]

				R. G. Pratt, G. A. Boehm, C. M. Kortepeter, J. A. Racoosin, B. A. Cohen, and D. D. Mikol Mitoxantrone treatment of multiple sclerosis: Safety considerations Neurology, December 27, 2005; 65(12): 1997 - 1997. [Full Text] [PDF]

				J. E Walker, S. N Giri, and S. B Margolin A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis Multiple Sclerosis, April 1, 2005; 11(2): 149 - 158. [Abstract] [PDF]

				B. A. Cohen and D. D. Mikol Mitoxantrone treatment of multiple sclerosis: Safety considerations Neurology, December 28, 2004; 63(12_suppl_6): S28 - S32. [Abstract] [Full Text]